Shares of Hologic, Inc. (NASDAQ:HOLX – Get Free Report) have been given a consensus recommendation of “Hold” by the eight ratings firms that are covering the company, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $86.89.
Several analysts have issued reports on HOLX shares. UBS Group raised their price target on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Needham & Company LLC lifted their target price on shares of Hologic from $83.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, February 2nd. Raymond James lifted their target price on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Finally, William Blair reiterated an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd.
Check Out Our Latest Stock Report on HOLX
Insider Activity at Hologic
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of Hologic by 5.1% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,448 shares of the medical equipment provider’s stock worth $2,569,000 after buying an additional 1,631 shares during the last quarter. LSV Asset Management lifted its stake in shares of Hologic by 307.5% during the 1st quarter. LSV Asset Management now owns 37,900 shares of the medical equipment provider’s stock worth $2,911,000 after buying an additional 28,600 shares during the last quarter. Raymond James Trust N.A. raised its stake in Hologic by 7.4% in the 1st quarter. Raymond James Trust N.A. now owns 6,875 shares of the medical equipment provider’s stock worth $528,000 after purchasing an additional 476 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Hologic by 4.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,305,399 shares of the medical equipment provider’s stock worth $177,098,000 after purchasing an additional 106,315 shares in the last quarter. Finally, Aviva PLC raised its stake in Hologic by 0.7% in the 1st quarter. Aviva PLC now owns 75,543 shares of the medical equipment provider’s stock worth $5,803,000 after purchasing an additional 513 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.
Hologic Trading Up 0.8 %
Hologic stock opened at $77.96 on Friday. The company has a 50 day moving average price of $74.82 and a 200 day moving average price of $71.88. Hologic has a 52 week low of $64.02 and a 52 week high of $87.88. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89. The firm has a market capitalization of $18.30 billion, a price-to-earnings ratio of 36.95, a P/E/G ratio of 2.58 and a beta of 1.00.
Hologic (NASDAQ:HOLX – Get Free Report) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. Hologic’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.07 EPS. Research analysts forecast that Hologic will post 4.02 EPS for the current year.
About Hologic
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
See Also
- Five stocks we like better than Hologic
- Find and Profitably Trade Stocks at 52-Week Lows
- 3 Value Stocks Too Small For Buffett’s Portfolio
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- Trading Halts Explained
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.